Reference | Method | No. of patients | Results | Dose |
---|---|---|---|---|
In vitro stimulation and expansion | ||||
Riddell et al. (1992) [22] | Allogeneic CMV-spec. CD8+ clones | 3 | 3/3 prevention of viremia and pneumonia | 3.3 × 107–109 cells/m2 |
Walter et al. (1995) [45] | Allogeneic CMV-spec. CD8+ clones phase I | 14 (11) | 11/11 prevention of CMV infection | 3.3 × 107–109 cells/m2 |
Einsele et al. (2002) [23] | Allogeneic CMV-spec. polyclonal CD8+ and CD4+ T cells | 8 | 5/7 evaluable patients eliminated infection | 107 cells/m2 |
Peggs et al. (2003) [46] | Allogeneic CMV-specific polyclonal CD8+ and CD4+ T cells | 16 | 14/16 no viral reactivation, reconstitution of antiviral immunity | 105 cells/kg |
Perruccio et al. (2005) [56] | Allogeneic CMV-specific CD4+ clones | 25 prophylaxis | 7/25 patients had CMV-reactivation, 5/25 patients developed CMV-disease (3 eliminated infection) | 105–3 × 106 cells/kg |
Meji et al. (2012) [57] | CMV-specific polyclonal CD8+ and CD4+ T cells phase I/II | 6 | 6/6 patients eliminated infection | 0.9 × 104–3.1 × 105 cells/kg |
Pei et al. (2017) [58] | CMV-specific cytokine induce effector cells phase I | 32 | 27/32 responded | 0.66–15.41 × 107 CD8+ and 0.68–9.25 × 105 CD4+ |
CMV-specific third-party CD8+ and CD4+ T cells phase I | 27 | 26/27 responded | 1.37–5.0 × 107 cells/m2 | |
Direct isolation via peptide-HLA multimers | ||||
Cobbold et al. (2005) [47] | Allogeneic CMV-specific CD8+ T cells using MHC-I-tetramers | 9 | 8/9 patients eliminated infection | 1.2–33 × 103 cells/kg |
Schmitt et al. (2011) [48] | Allogeneic CMV-specific CD8+ T cells using MHC-I-streptamers | 2 | 2/2 control of CMV-viremia | 0.37 and 2.2 × 105 cells/kg |
Uhlin et al. (2012) [60] | Allogeneic CMV-specific CD8+ T cells using MHC-I-pentamers | 5 | 4/5 responders | 0.8–24.6 × 104 cells/kg |
Blyth et al. (2013) [61] | Allogeneic CMV-specific polyclonal CD8+ and CD4+ T cells phase II | 50 Prophylaxis | 41/50 did not require CMV-directed pharmacotherapy | 2 × 107 cells/m2 |
Neuenhahn et al. (2017) [12] | Allogeneic CMV-specific CD8+ T cells using MHC-I-streptamers phase I/IIa | 16 | Stem cell donor-derived: 7/7 responders third-party transfer: 5/8 responders | 6.3 × 106 cells (HSCT donor) 1.4 × 107 cells (third-party donor) |
Direct isolation via cytokine-capture technique | ||||
Feuchtingeret al. (2010) [28] | CMV-specific polyclonal CD8+ and CD4+ T cells | 18 | 15/18 responders | 1.2–166 × 103 cells/kg |
Peggs et al. (2011) [62] | CMV-specific polyclonal CD8+ and CD4+ T cells phase I/II | 18 | Prophylaxis: 6/7 virus-free Pre-emptive: 2/11 required no antiviral drug treatment | Median: 3.5 × 104 cells/kg |
Kà llay et al. (2018) [43] | CMV-specific polyclonal CD8+ and CD4+ T cells | 3 | 2/3 viral clearance 1/3 decrease in viral load | 7.5–16.2 × 104 cells/kg |